Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA determines that its questions have been satisfactorily answered.
Advertisement

Related Content

Wyeth To Revisit Launch Plans For Effexor XR Follow-On
Wyeth To Revisit Launch Plans For Effexor XR Follow-On
Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
FDA Cancels Advisory Committee Meeting On J&J’s Paliperidone ER
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Effexor XR Follow-On Desvenlafaxine NDA Submitted
Effexor XR Follow-On Desvenlafaxine NDA Submitted

Topics

Advertisement
UsernamePublicRestriction

Register

PS064723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel